Asia
Hualan Gets China Clinical Trial Approval for Influenza Jab
China's drug regulator approved Hualan Biological Engineering (SHE:002007) subsidiary Hualan Biological Vaccine's clinical trial for its novel adjuvanted influenza virus split vaccine.The vaccine helps with immunity against influenza, especially in elderly and immunocompromised patients, according to a Saturday disclosure to the Shenzhen bourse.
SHE:002007
